

## **PRO-PHARMACEUTICALS' EXECUTIVES CONTRIBUTE TO DEFINITIVE BOOK ON GALECTINS**

### **Pro-Pharmaceuticals' DAVANAT® Targets Galectin Receptors on Cancer Cells**

**Newton, Mass. (June 25, 2008) Pro-Pharmaceuticals, Inc. (Amex: PRW)**, a Company developing proprietary carbohydrate-based therapeutic compounds to treat cancer and fibrosis, today announced two of its executives and a member of its Scientific Advisory Board edited a new book "*Galectins*" and authored one of the chapters. The book offers a comprehensive guide to the current understanding of galectins, their promising potential in drug design and the role galectins play in tumor growth, cancer, angiogenesis, resistance to chemotherapy, and the initiation and proliferation of organ fibrosis.

"This is the first book focusing on galectins and their biomedical applications. The book is inspired by topics discussed at the symposium 'Galectins: Structures, Functions, and Therapeutic Targets' sponsored by Pro-Pharmaceuticals as part of the American Chemical Society's 234th annual meeting held in 2007," said Anatole Klyosov, Ph.D., D.Sc., Chief Scientist, Pro-Pharmaceuticals. "We believe our expertise in developing carbohydrate-based compounds that target galectin receptors offers opportunities for the advanced treatment of cancer, fibrosis and inflammatory diseases."

Contributing to the book was Anatole Klyosov; David Platt; Ph.D., Chief Executive Officer, Pro-Pharmaceuticals; and Zbigniew J. Witczak, a member of Pro-Pharmaceuticals Scientific Advisory Board; Associate Professor at the Nesbitt School of Pharmacy, Wilkes University, and former chair of the American Chemical Society's Division of Carbohydrate Chemistry.

The book, published by John Wiley & Sons, Inc., is a reference on galectins for organic, medicinal, carbohydrate, and pharmaceutical chemists, biochemists, molecular and cell biologists, pharmacologists, and cancer researchers, as well as clinicians and drug developers. The editors have compiled articles from leading experts on galectins and their biomedical applications.

"*Galectins*" includes:

- An overview of early galectin research
- An explanation of the nature of galectins
- A discussion of the structure and functions of galectins, their ligand specificity and molecular mechanisms of action, and the localization of galectins in the cell
- An exploration of the roles galectins play in tumor growth and cancer, fibrosis, inflammation, and immunity
- The role of galectins in organ fibrosis
- A discussion of the effect of galectins on cell migration, angiogenesis, and chemo-resistance
- An introduction to new approaches to designing galectin inhibitors

#### **About DAVANAT®**

DAVANAT®, the Company's leading drug candidate, is a proprietary polysaccharide polymer that has a mechanism of action based on affecting lectins—specific receptors that bind only to a particular type of carbohydrate. The drug binds to galectins on tumor cells while selectively avoiding surrounding healthy tissue. This form of targeted therapy may allow for higher doses of chemotherapy administration with no increase in toxicity.

## **Pro-Pharmaceuticals, Inc. – Advancing Drugs Through Glycoscience®**

Pro-Pharmaceuticals is a clinical stage pharmaceutical company engaged in the discovery, development and commercialization of carbohydrate-based, target therapeutic compounds for advanced treatment of cancer, liver, microbial and inflammatory diseases. The Company's initial focus is the development of carbohydrate polymers to treat cancer patients. DAVANAT®, the Company's lead product candidate, is a polysaccharide polymer that is in Phase II trials for colorectal and biliary cancer. The Company's technology is also being used to develop new chemical entities to treat liver and kidney fibrosis. The Company is headquartered in Newton, Mass. Additional information is available at [www.pro-pharmaceuticals.com](http://www.pro-pharmaceuticals.com).

**FORWARD LOOKING STATEMENTS:** Any statements in this news release about this or future financings, expectations, plans and prospects for the Company, including without limitation, statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements as defined in the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding the expected closing of the private placement and the anticipated use of proceeds. These forward-looking statements are based on management's current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those, described in such statements. More information about those risks and uncertainties is contained in the Company's quarterly or annual report, Form 8-K and in the Company's other reports filed with the Securities and Exchange Commission. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.

Contact: Pro-Pharmaceuticals, Inc., Anthony D. Squeglia: 617.559.0033; [squeglia@pro-pharmaceuticals.com](mailto:squeglia@pro-pharmaceuticals.com).

DAVANAT and Advancing Drugs Through Glycoscience are registered trademarks of Pro-Pharmaceuticals.